Company / Operating Cash Flow
Regeneron Pharmaceuticals Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
$5.0B
FY2025
5-year range
$2.4B / $5.0B
FY2021-FY2025
Trend
+12.6%
vs FY2024
Sector context
#10 of 216
Health Care
What the data says
Among 216 Health Care companies, Regeneron Pharmaceuticals is in the top 5% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from $1.3B in FY2017 to $5.0B in FY2025.
Based on SEC 10-K filings.
$5.0B in FY2025 with a 5-year CAGR of +17.8%. Top quartile in the Health Care sector.
Improved from $4.6B to $5.0B over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- +23.9%
- 5-Year CAGR
- +17.8%
- 10-Year CAGR
- -
Sector benchmark
+655.8% above sector average
Key checks
Key Insights
- 5-year CAGR of +17.8%, indicating consistent growth.
- In FY2025, operating cash flow increased 12.6% year-over-year.
- Ranks #10 out of 216 companies in the Health Care sector.
- Lowest operating cash flow in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 3.03 (safe zone, above 2.9 threshold)
- Strong profit margin: 32.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.0B | +12.6% |
| FY2024 | $4.4B | -3.8% |
| FY2023 | $4.6B | +75.5% |
| FY2022 | $2.6B | +7.7% |
| FY2021 | $2.4B | +10.7% |
| FY2020 | $2.2B | -9.7% |
| FY2019 | $2.4B | +10.7% |
| FY2018 | $2.2B | +67.9% |
| FY2017 | $1.3B | -12.0% |
| FY2016 | $1.5B | +11.7% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026